Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: A multi‐center, open‐label, randomized controlled trial
Usha Perepu, Isaac Chambers, Abdul Wahab, Patrick Ten Eyck, Chaorong Wu, Sanjana Dayal, Grerk Sutamtewagul, Steven R. Bailey, Lori J. Rosenstein, Steven R. Lentz
Topics & Concepts
Coronavirus disease 2019 (COVID-19)MedicineRandomized controlled trialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakOpen labelVirologyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and ThrombosisVenous Thromboembolism Diagnosis and Management